Home ADNKronos The European Commission Approves Label Update for TAKHZYRO® (lanadelumab), Expanding Its Use to a Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (HAE)
 

Immediapress

The European Commission Approves Label Update for TAKHZYRO® (lanadelumab), Expanding Its Use to a Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (HAE)

 

(Adnkronos) - -  TAKHZYRO® is the First Routine Prevention Treatment of HAE Approved in the EU for Patients Under the Age of Six. -  The therapeutical indication for TAKHZYRO® has been extended to patients aged 2 years and older.1  -  Offers a

I contenuti di VeneziePost sono a pagamento.
Per visualizzare questo articolo e tutti i nostri contenuti scegli tra queste opzioni
Sei già iscritto a VeneziePost?
Clicca qui sotto e inserisci le tue credenziali
Accedi
Facebook Twitter Linkedin Email